Veradermics, Inc (MANE) Stock
8 of the hedge funds AlphaScala tracks reported MANE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $230.85M. Company insiders reported 0 open-market buys and 15 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own MANE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.88M | $230.85M | +3% |
| Viking Global Investors Andreas Halvorsen | 1.56M | $191.97M | -8% |
| D.E. Shaw David Shaw | 1.01M | $124.62M | +655% |
| Maverick Capital Lee Ainslie | 790K | $97.12M | NEW |
| Marshall Wace | 586K | $71.99M | -11% |
| Renaissance Technologies Jim Simons (founder) | 82K | $10.06M | NEW |
| Millennium Management Israel Englander | 50K | $6.15M | -59% |
| Blackstone | 15K | $1.86M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Veradermics, Inc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Montanova Capital, Llc | Director | SELL | 690.6K | $74.1M |
| Aug 19, 26 | Montanova Capital, Llc | Director | SELL | 59.4K | $6.4M |
| Aug 17, 26 | Waldman Reid Alexander | Chief Executive Officer | SELL | 11.5K | $1.2M |
| Aug 17, 26 | Waldman Reid Alexander | Chief Executive Officer | SELL | 25.2K | $2.7M |
| Aug 17, 26 | Waldman Reid Alexander | Chief Executive Officer | SELL | 27.5K | $3.0M |
| Aug 17, 26 | Waldman Reid Alexander | Chief Executive Officer | SELL | 3.0K | $328K |
| Aug 17, 26 | Waldman Reid Alexander | Chief Executive Officer | SELL | 249 | $28K |
| Aug 17, 26 | Durso Timothy August | Chief Technical Officer | SELL | 7.9K | $845K |
| Aug 17, 26 | Durso Timothy August | Chief Technical Officer | SELL | 16.3K | $1.8M |
| Aug 17, 26 | Durso Timothy August | Chief Technical Officer | SELL | 16.8K | $1.8M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →MANE price chart
Powered by TradingViewWhat does Veradermics, Inc do?
Veradermics Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for prevalent aesthetic and dermatological conditions. Its primary focus centers on pattern hair loss, affecting approximately 50 million men and 30 million women in the United States, where current treatments suffer from high dissatisfaction due to slow results, side effects, and inconvenient administration. The company's lead candidate, VDPHL01, represents an oral, non-hormonal, extended-release formulation of minoxidil, originally a hypertension drug noted for hair growth side effects. This proprietary design aims to optimize hair restoration by maximizing plasma concentrations for follicular benefits while minimizing cardiac risks associated with immediate-release versions. Veradermics is advancing VDPHL01 through a registration-directed clinical program, including fully enrolled Phase 2/3 trials in males and ongoing Phase 3 trials in females, targeting FDA approval via a 505(b)(2) New Drug Application. Founded in 2019 and headquartered in New Haven, Connecticut, Veradermics addresses a $9 billion U.S. market opportunity in hair loss treatments, backed by a seasoned team with deep dermatology expertise.